Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
WPI | Ann: Quarterly Activities Report and Appendix 5B June 2015 | 26/08/18 | 56 | 19K | |||
|
|||||||
WPI | asx | 28/07/16 | 8 | 2.7K | |||
|
|||||||
WPI | CIZ | 08/04/16 | 11 | 7.5K | |||
|
|||||||
WPI | Ann: Results of General Meeting of Shareholders | 18/03/16 | 48 | 17K | |||
|
|||||||
WPI | Meeting today | 11/03/16 | 2 | 1.3K | |||
|
|||||||
WPI | next in line | 10/03/16 | 103 | 30K | |||
|
|||||||
WPI | Ann: Notice of General Meeting and Proxy Form | 04/03/16 | 29 | 7.4K | |||
|
|||||||
WPI | Ann: December 2015 Interim Financial Report | 04/03/16 | 0 | 583 | |||
|
See All Discussions